FDA OKs MiddleBrook's Moxatag

01/25/2008 | Washington Post, The

The FDA has approved MiddleBrook Pharmaceuticals' once-daily amoxicillin candidate Moxatag for treating strep throat in adolescents and adults, the company announced Thursday. Moxatag, which was developed using MiddleBrook's Pulsys time-release technology, is expected on the market in the last quarter of the year.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD